Competitor Analysis: CD20 Antibodies


January 25, 2009
37 Pages - SKU: LAM2271379
License type:
Global Markets for Orphan Drugs – Focus on Biologics
6/1/2013 | published by: BCC Research
This report provides: An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence and advantages inherent in orphan drug designation and future growth trends; this report focuses on  |  read more...
$4,400.00
Global Markets for Orphan Drugs – Focus on Non-Biologics
6/1/2013 | published by: BCC Research
This report provides: An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence and advantages inherent in orphan drug designation and future growth trends; this report focuses on  |  read more...
$4,400.00
Antibody Drug Conjugates Market, 2012-2023
5/31/2013 | published by: Roots Analysis Pvt. Ltd.
Antibody Drug Conjugates (ADC) are a new class of biologic therapeutics. These are complex molecules comprising of an antibody linked to few cytotoxin molecules through linker technology. This class of biologics is attracting the attention  |  read more...
$1,699.00
Triple Analysis: Melanoma, Antibodies and Peptides
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized criteria in a  |  read more...
$5,175.00
Triple Analysis: Melanoma, Cancer Vaccines and Antibodies
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according  |  read more...
$5,175.00
Monoclonal Antibodies Partnering Terms and Agreements
6/1/2013 | published by: Current Partnering
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right  |  read more...
$3,795.00
Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in  |  read more...
$5,175.00
Triple Analysis: Melanoma, Protein Kinase Inhibitors and Antibodies
6/12/2013 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is evaluated  |  read more...
$5,175.00
PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013
5/27/2013 | published by: GlobalData
PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013 Summary GlobalData’s PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013, provides strategic analysis of the global biosimilars  |  read more...
$2,995.00
Pharmaceutical Market India: A Comprehensive Industry Analysis
5/20/2013 | published by: Kelly Scientific Publications
Pharmaceutical Market India: A Comprehensive Industry Analysis provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report, Pharmaceutical Market India:  |  read more...
$2,620.00